157 related articles for article (PubMed ID: 11561696)
1. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea.
Pro B; Lozano R; Ajani JA
Invest New Drugs; 2001; 19(4):341-3. PubMed ID: 11561696
[TBL] [Abstract][Full Text] [Related]
2. Control of irinotecan-induced diarrhea by octreotide after loperamide failure.
Barbounis V; Koumakis G; Vassilomanolakis M; Demiri M; Efremidis AP
Support Care Cancer; 2001 Jun; 9(4):258-60. PubMed ID: 11430421
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
Saliba F; Hagipantelli R; Misset JL; Bastian G; Vassal G; Bonnay M; Herait P; Cote C; Mahjoubi M; Mignard D; Cvitkovic E
J Clin Oncol; 1998 Aug; 16(8):2745-51. PubMed ID: 9704727
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
5. Octreotide in the treatment of severe chemotherapy-induced diarrhea.
Zidan J; Haim N; Beny A; Stein M; Gez E; Kuten A
Ann Oncol; 2001 Feb; 12(2):227-9. PubMed ID: 11300329
[TBL] [Abstract][Full Text] [Related]
6. [Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Couteau C; Yakendji K; Terret C; Goncalves E; Armand JP
Bull Cancer; 1996 Jan; 83(1):3-10. PubMed ID: 8672854
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.
Abigerges D; Armand JP; Chabot GG; Da Costa L; Fadel E; Cote C; Hérait P; Gandia D
J Natl Cancer Inst; 1994 Mar; 86(6):446-9. PubMed ID: 8120919
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg ML; Eckardt JR; Kuhn JG; Burris HA; Nelson J; Hilsenbeck SG; Rodriguez GI; Thurman AM; Smith LS; Eckhardt SG; Weiss GR; Elfring GL; Rinaldi DA; Schaaf LJ; Von Hoff DD
J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
[TBL] [Abstract][Full Text] [Related]
9. Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy.
Rosenoff SH
Eur J Cancer Care (Engl); 2004 Sep; 13(4):380-3. PubMed ID: 15305907
[TBL] [Abstract][Full Text] [Related]
10. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.
Lenfers BH; Loeffler TM; Droege CM; Hausamen TU
Ann Oncol; 1999 Oct; 10(10):1251-3. PubMed ID: 10586346
[TBL] [Abstract][Full Text] [Related]
11. Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma.
Petrelli NJ; Rodriguez-Bigas M; Rustum Y; Herrera L; Creaven P
Cancer; 1993 Sep; 72(5):1543-6. PubMed ID: 8348489
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy-induced diarrhea].
Kobayashi K
Gan To Kagaku Ryoho; 2003 Jun; 30(6):765-71. PubMed ID: 12852342
[TBL] [Abstract][Full Text] [Related]
14. [Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats].
Takasuna K; Kasai Y; Kitano Y; Mori K; Kakihata K; Hirohashi M; Nomura M
Nihon Yakurigaku Zasshi; 1995 Jun; 105(6):447-60. PubMed ID: 7557733
[TBL] [Abstract][Full Text] [Related]
15. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.
Rosenoff S
Support Care Cancer; 2004 Aug; 12(8):561-70. PubMed ID: 15160318
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
Michael M; Brittain M; Nagai J; Feld R; Hedley D; Oza A; Siu L; Moore MJ
J Clin Oncol; 2004 Nov; 22(21):4410-7. PubMed ID: 15514383
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
[TBL] [Abstract][Full Text] [Related]
18. Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.
Schmittel A; Jahnke K; Thiel E; Keilholz U
Ann Oncol; 2004 Aug; 15(8):1296. PubMed ID: 15277273
[No Abstract] [Full Text] [Related]
19. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
Hoff PM; Saragiotto DF; Barrios CH; del Giglio A; Coutinho AK; Andrade AC; Dutra C; Forones NM; Correa M; Portella Mdo S; Passos VQ; Chinen RN; van Eyll B
J Clin Oncol; 2014 Apr; 32(10):1006-11. PubMed ID: 24516038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]